Status:
UNKNOWN
The Use of Sugammadex in the Critically Ill
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Critical Illness
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Moderate and Deep neuromuscular blockade (rocuronium administered to a train of four count 0 and post-tetanic count of 1-2) in critically ill patients needing intubation or procedures can be reversed ...
Detailed Description
The Critically ill is a special population needing immediate and aggressive treatments and interventions. Neuromuscular blockade is frequently used to secure an airway, optimize ventilation/oxygenatio...
Eligibility Criteria
Inclusion
- Adult patients requiring intubation in the intensive care unit
Exclusion
- Patients younger than 18 yr, to have known or suspected neuromuscular disease, allergies to medications to be used during intubation, a (family) history of malignant hyperthermia or severe renal insufficiency (glomerular filtration rate \<30 ml/h) will not be eligible.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03791801
Start Date
September 1 2019
End Date
July 1 2021
Last Update
August 21 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University Health Center
Montreal, Quebec, Canada, H3A 1A1
2
MUHC
Montreal, Quebec, Canada, H4A 3J1